UBS Group’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $576K | Buy |
265,535
+3,015
| +1% | +$7.48K | ﹤0.01% | 5985 |
|
|
2025
Q4 | $473K | Buy |
262,520
+72,244
| +38% | +$148K | ﹤0.01% | 6113 |
|
|
2025
Q3 | $422K | Buy |
190,276
+115,126
| +153% | +$187K | ﹤0.01% | 6217 |
|
|
2025
Q2 | $111K | Buy |
75,150
+73,063
| +3,501% | +$149K | ﹤0.01% | 7147 |
|
|
2025
Q1 | $5.34K | Sell |
2,087
-16,091
| -89% | -$38.4K | ﹤0.01% | 9009 |
|
|
2024
Q4 | $34.2K | Buy |
18,178
+17,886
| +6,125% | +$25.3K | ﹤0.01% | 7529 |
|
|
2024
Q3 | $298 | Sell |
292
-15
| -5% | -$16 | ﹤0.01% | 9014 |
|
|
2024
Q2 | $359 | Sell |
307
-67,649
| -100% | -$79.9K | ﹤0.01% | 8955 |
|
|
2024
Q1 | $85.6K | Sell |
67,956
-6,762
| -9% | -$10.1K | ﹤0.01% | 6290 |
|
|
2023
Q4 | $133K | Buy |
74,718
+37,658
| +102% | +$58.6K | ﹤0.01% | 6024 |
|
|
2023
Q3 | $61.5K | Sell |
37,060
-14,980
| -29% | -$26.9K | ﹤0.01% | 6168 |
|
|
2023
Q2 | $104K | Buy |
52,040
+47,349
| +1,009% | +$113K | ﹤0.01% | 5985 |
|
|
2023
Q1 | $9.85K | Buy |
4,691
+4,571
| +3,809% | +$8.02K | ﹤0.01% | 7621 |
|
|
2022
Q4 | $164 | Sell |
120
-10,998
| -99% | -$12.1K | ﹤0.01% | 10341 |
|
|
2022
Q3 | $11K | Buy |
11,118
+10,998
| +9,165% | +$12.2K | ﹤0.01% | 8318 |
|
|
2022
Q2 | $0 | Hold |
120
| – | – | ﹤0.01% | 10777 |
|
|
2022
Q1 | $0 | Hold |
120
| – | – | ﹤0.01% | 10746 |
|
|
2021
Q4 | $0 | Sell |
120
-2,194
| -95% | -$2.3K | ﹤0.01% | 10589 |
|
|
2021
Q3 | $3K | Buy |
2,314
+389
| +20% | +$591 | ﹤0.01% | 8827 |
|
|
2021
Q2 | $3K | Sell |
1,925
-270
| -12% | -$929 | ﹤0.01% | 8830 |
|
|
2021
Q1 | $10K | Buy |
2,195
+998
| +83% | +$4.65K | ﹤0.01% | 7937 |
|
|
2020
Q4 | $5K | Sell |
1,197
-3,315
| -73% | -$11.9K | ﹤0.01% | 7839 |
|
|
2020
Q3 | $17K | Buy |
4,512
+859
| +24% | +$3.11K | ﹤0.01% | 6447 |
|
|
2020
Q2 | $14K | Buy |
3,653
+3,474
| +1,941% | +$11.9K | ﹤0.01% | 6796 |
|
|
2020
Q1 | $0 | Buy |
179
+129
| +258% | +$427 | ﹤0.01% | 8292 |
|
|
2019
Q4 | $0 | Sell |
50
-6,682
| -99% | -$16.5K | ﹤0.01% | 8333 |
|
|
2019
Q3 | $14K | Sell |
6,732
-13,242
| -66% | -$39.5K | ﹤0.01% | 6953 |
|
|
2019
Q2 | $93K | Buy |
19,974
+4,229
| +27% | +$17.9K | ﹤0.01% | 5426 |
|
|
2019
Q1 | $69K | Sell |
15,745
-113
| -0.7% | -$509 | ﹤0.01% | 5328 |
|
|
2018
Q4 | $49K | Buy |
15,858
+12,419
| +361% | +$59K | ﹤0.01% | 6108 |
|
|
2018
Q3 | $25K | Buy |
3,439
+2,379
| +224% | +$11.9K | ﹤0.01% | 6670 |
|
|
2018
Q2 | $4K | Sell |
1,060
-10,098
| -91% | -$44.9K | ﹤0.01% | 7560 |
|
|
2018
Q1 | $60K | Buy |
11,158
+4,231
| +61% | +$27.8K | ﹤0.01% | 5579 |
|
|
2017
Q4 | $46K | Sell |
6,927
-164
| -2% | -$1.11K | ﹤0.01% | 5901 |
|
|
2017
Q3 | $41K | Sell |
7,091
-29,878
| -81% | -$191K | ﹤0.01% | 5937 |
|
|
2017
Q2 | $309K | Buy |
36,969
+36,919
| +73,838% | +$347K | ﹤0.01% | 4464 |
|
|
2017
Q1 | $1K | Hold |
50
| – | – | ﹤0.01% | 7443 |
|
|
2016
Q4 | $0 | Sell |
50
-868
| -95% | -$3.88K | ﹤0.01% | 7973 |
|
|
2016
Q3 | $5K | Buy |
918
+365
| +66% | +$2.28K | ﹤0.01% | 7129 |
|
|
2016
Q2 | $3K | Buy |
553
+503
| +1,006% | +$4.02K | ﹤0.01% | 7335 |
|
|
2016
Q1 | $0 | Sell |
50
-30
| -38% | -$257 | ﹤0.01% | 8039 |
|
|
2015
Q4 | $1K | Sell |
80
-289
| -78% | -$2.94K | ﹤0.01% | 8164 |
|
|
2015
Q3 | $4K | Buy |
369
+289
| +361% | +$4.59K | ﹤0.01% | 7837 |
|
|
2015
Q2 | $2K | Sell |
80
-436
| -84% | -$9.04K | ﹤0.01% | 8204 |
|
|
2015
Q1 | $9K | Buy |
516
+351
| +213% | +$6.87K | ﹤0.01% | 7724 |
|
|
2014
Q4 | $3K | Buy |
+165
| New | +$3.54K | ﹤0.01% | 9258 |
|
Other funds holding PLX
MCO
SWP
VPM
PFS
OM
UBS Group's PLX Position: Q1 2026 in Review
UBS Group increased its Protalix BioTherapeutics (PLX) stake by 1.1% in Q1 2026, buying an estimated $7.48K and bringing the position to 265,535 shares worth $576K. The position accounts for ﹤0.01% of the portfolio, ranked #5985.
UBS Group first reported a position in PLX in Q4 2014 and has held it in 46 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.
- UBS Group held 265,535 shares of Protalix BioTherapeutics worth $576K as of Q1 2026.
- UBS Group bought 3,015 Protalix BioTherapeutics shares in Q1 2026, an estimated $7.48K.
- Protalix BioTherapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5985 holding.
- UBS Group first reported a position in Protalix BioTherapeutics in Q4 2014 and has held it in 46 quarters since.
- 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.